Influence of tumour micro-environment heterogeneity on therapeutic response

Tumour formation involves the co-evolution of neoplastic cells together with extracellular matrix, tumour vasculature and immune cells. Successful outgrowth of tumours and eventual metastasis is not determined solely by genetic alterations in tumour cells, but also by the fitness advantage such mutations confer in a given environment. As fitness is context dependent, evaluating tumours as complete organs, and not simply as masses of transformed epithelial cells, becomes paramount. The dynamic tumour topography varies drastically even throughout the same lesion. Heterologous cell types within tumours can actively influence therapeutic response and shape resistance.

[1]  R. Weinberg,et al.  Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[3]  B. Jaffee,et al.  Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. , 1998, Journal of immunology.

[4]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[5]  R. Khokha,et al.  Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Aird,et al.  Vascular-bed--specific hemostasis and hypercoagulable states. , 1999, The New England journal of medicine.

[7]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Barcellos-Hoff,et al.  Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. , 2000, Cancer research.

[9]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[10]  J. Campisi,et al.  Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[12]  J. Verdebout,et al.  The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2002, British Journal of Cancer.

[13]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[14]  R. Kalluri.  Basement membranes: structure, assembly and role in tumour angiogenesis , 2003, Nature reviews. Cancer.

[15]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[16]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[17]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[18]  Patrick Nicolas,et al.  Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. , 2004, Cancer research.

[19]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[20]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[21]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Dachman,et al.  Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jun Yao,et al.  Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.

[24]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[25]  研宙 大内田,et al.  Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions , 2005 .

[26]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[27]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[28]  B. Robinson,et al.  Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.

[29]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[30]  Howard Y. Chang,et al.  Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs , 2006, PLoS genetics.

[31]  Martin Widschwendter,et al.  Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. , 2006, Cancer research.

[32]  R. Benamouzig,et al.  Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature , 2005, British Journal of Cancer.

[33]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[35]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[36]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Platzer,et al.  Breast-cancer stromal cells with TP53 mutations and nodal metastases. , 2007, The New England journal of medicine.

[38]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[39]  P. Kufer,et al.  Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. , 2006, Journal of immunotherapy.

[40]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[41]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Thomas D. Wu,et al.  Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer , 2008, Clinical Cancer Research.

[43]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[44]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[45]  Kylie L. Gorringe,et al.  No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas , 2008, Nature Genetics.

[46]  Fabian Kiessling,et al.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.

[47]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[48]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[49]  G. Hutchins,et al.  Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.

[50]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[51]  Gordon C Jayson,et al.  Angiogenesis as a therapeutic target in cancer. , 2008, Clinical medicine.

[52]  J. Schlom,et al.  Translational Research Working Group Developmental Pathway for Immune Response Modifiers , 2008, Clinical Cancer Research.

[53]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[54]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[55]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[57]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[58]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[59]  F. D. de Sauvage,et al.  Paracrine Hedgehog signaling in cancer. , 2009, Cancer research.

[60]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[61]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[62]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[63]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[64]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[65]  Lin Cui,et al.  &agr;-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma , 2010, Pancreas.

[66]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[67]  M. Wicha,et al.  Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. , 2010, Cancer research.

[68]  M. Karin,et al.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.

[69]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[70]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[71]  Z. Werb,et al.  Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.

[72]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[73]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[74]  T. Ogawa,et al.  Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome , 2012, Breast Cancer.

[75]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[76]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[77]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[78]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  G. Coukos,et al.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.

[80]  Piyush B. Gupta,et al.  Functional Heterogeneity of Breast Fibroblasts Is Defined by a Prostaglandin Secretory Phenotype that Promotes Expansion of Cancer-Stem Like Cells , 2011, PloS one.

[81]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[82]  A. Jubb,et al.  Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases , 2011, British Journal of Cancer.

[83]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[84]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[85]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[86]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[87]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[88]  E. Van Cutsem,et al.  Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[90]  Hiroyuki Tomita,et al.  Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. , 2011, Cancer cell.

[91]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[92]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[93]  M. Lubberink,et al.  Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. , 2012, Cancer cell.

[94]  J. Berlin,et al.  A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer , 2012, Clinical Cancer Research.

[95]  J. Thigpen,et al.  A Phase 3 Trial of Bevacizumab in Ovarian Cancer , 2012 .

[96]  Mallika Singh,et al.  Modeling and predicting clinical efficacy for drugs targeting the tumor milieu , 2012, Nature Biotechnology.

[97]  L. Zitvogel,et al.  Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system , 2012, Nature Medicine.

[98]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[99]  B. Karlan,et al.  A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission , 2012, Clinical Cancer Research.

[100]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[101]  I. Kasman,et al.  Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models , 2012, The Journal of pathology.

[102]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[103]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[104]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[105]  Judith Campisi,et al.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B , 2012, Nature Medicine.

[106]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[107]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[108]  P. Watson,et al.  CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer , 2012, Clinical Cancer Research.

[109]  P. Hegde,et al.  Predictive Impact of Circulating Vascular Endothelial Growth Factor in 4 Phase Iii Trials Evaluating Bevacizumab Departments of 1 , 2022 .

[110]  C. Payne,et al.  Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[111]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[112]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[113]  J. Jonkers,et al.  Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system , 2012, Nature Medicine.

[114]  M. Vannier,et al.  A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. , 2012 .

[115]  Zongguang Zhou,et al.  A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy , 2013, Journal of Cancer Research and Clinical Oncology.

[116]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[117]  F. Peale,et al.  Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors , 2012, The Journal of pathology.

[118]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[119]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[120]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[121]  B. Monk,et al.  Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  P. Carmeliet,et al.  Markers of response for the antiangiogenic agent bevacizumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  S. Bates,et al.  Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma , 2013, Cell reports.

[124]  M. Vannier,et al.  Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study. , 2013 .

[125]  L. Ellis,et al.  Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. , 2013, Cancer cell.

[126]  F. Peale,et al.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment , 2013, Proceedings of the National Academy of Sciences.

[127]  A. Orimo,et al.  Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells , 2013, Journal of cellular physiology.